Analysts Are More Bearish On Niagen Bioscience, Inc. (NASDAQ:NAGE) Than They Used To Be

Simply Wall St.11-10

One thing we could say about the analysts on Niagen Bioscience, Inc. (NASDAQ:NAGE) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682396512?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/5221000-choice1-card/1789035183893","is_english":true,"pubTime":"2026-11-10 18:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682396512","market":"us","top_or_hot":-1,"title":"Analysts Are More Bearish On Niagen Bioscience, Inc. (NASDAQ:NAGE) Than They Used To Be","media":"Simply Wall St.","content":"<div>\n<p>One thing we could say about the analysts on Niagen Bioscience, Inc. (NASDAQ:NAGE) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/analysts-are-more-bearish-on-niagen-bioscience-inc-nasdaqnag\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts Are More Bearish On Niagen Bioscience, Inc. (NASDAQ:NAGE) Than They Used To Be</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts Are More Bearish On Niagen Bioscience, Inc. (NASDAQ:NAGE) Than They Used To Be\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-10 18:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/analysts-are-more-bearish-on-niagen-bioscience-inc-nasdaqnag><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One thing we could say about the analysts on Niagen Bioscience, Inc. (NASDAQ:NAGE) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/analysts-are-more-bearish-on-niagen-bioscience-inc-nasdaqnag\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/analysts-are-more-bearish-on-niagen-bioscience-inc-nasdaqnag","article_id":"2682396512","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/5221000-choice1-card/1789035183893"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/analysts-are-more-bearish-on-niagen-bioscience-inc-nasdaqnag","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682396512","pubTimestamp":1794306459,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 10, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","VOTE":"TCW Transform 500 ETF","QID":"两倍做空纳斯达克指数ETF-ProShares","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","QQQE":"Direxion NASDAQ-100 Equal Weighted Index ETF","SQQQ":"纳指三倍做空ETF","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","IYW":"美国科技ETF-iShares","ONEQ":"Fidelity NASDAQ Composite Index ETF","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","QDTE":"Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF","QYLG":"Nasdaq 100 Covered Call & Growth ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","RGLO":"Global Equity Active ETF","TQQQ":"纳指三倍做多ETF","VGFPF":"Vanguard Funds PLC","GXDW":"Global X Dorsey Wright Thematic ETF","TQQY":"GraniteShares YieldBOOST QQQ ETF",".IXIC":"NASDAQ Composite","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","BK4183":"个人用品","NDX":"纳斯达克100指数","JOYT":"JPMorgan Equity and Options Total Return ETF","QQQM":"NASDAQ100指数ETF-Invesco","03086":"华夏纳指","TECS":"Direxion Daily Technology Bear 3X ETF","PSQ":"做空纳斯达克100指数ETF-ProShares","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","FTEC":"Fidelity MSCI Information Techno","QQQ":"纳指100ETF","NAGE":"Niagen Bioscience","QQQA":"ProShares Nasdaq-100 Dorsey Wright Momentum ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares"},"translate_title":"分析师对 Niagen Bioscience, Inc.（纳斯达克股票代码：NAGE）比以前更加悲观","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/b52dfc88bae3c13e14eb69bbdd04a87f","symbols_score_info":{"IYW":0.6,"PSQ":0.6,"JEPQ":0.6,"NQmain":0.6,"FTEC":0.6,"QID":0.6,"QQQM":0.6,"GXDW":0.65,"03086":0.6,"TQQY":0.6,"QLD":0.6,"QYLG":0.6,"FEBU":0.65,"ONEQ":0.6,"MNQmain":0.6,"GPIQ":0.6,"QQQ":0.6,"TQQQ":0.6,"RGLO":0.65,"PMDE":0.65,"NDX":0.6,"QDTE":0.6,".IXIC":1.5,"QQQE":0.6,"NAGE":1.5,"JOYT":0.65,"DECU":0.65,"QQQJ":0.6,"VGFPF":0.65,"VOTE":0.65,"SQQQ":0.6,"TECS":0.6,"QQQA":0.6,"QQQY":0.6},"content_text":"One thing we could say about the analysts on Niagen Bioscience, Inc. (NASDAQ:NAGE) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization.   Both revenue and earnings per share (EPS) estimates were cut sharply as analysts factored in the latest outlook for the business, concluding that they were too optimistic previously.   This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Following the downgrade, the latest consensus from Niagen Bioscience's six analysts is for revenues of US$137m in 2027, which would reflect a notable 12% improvement in sales compared to the last 12 months.       Statutory earnings per share are anticipated to tumble 63% to US$0.048 in the same period.        Before this latest update, the analysts had been forecasting revenues of US$155m and earnings per share (EPS) of US$0.17 in 2027.        It looks like analyst sentiment has declined substantially, with a measurable cut to revenue estimates and a large cut to earnings per share numbers as well.     Check out our latest analysis for Niagen Bioscience NasdaqCM:NAGE Earnings and Revenue Growth November 10th 2026  The consensus price target fell 12% to US$10.67, with the weaker earnings outlook clearly leading analyst valuation estimates.        Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry.     We would highlight that Niagen Bioscience's revenue growth is expected to slow, with the forecast 9.6% annualised growth rate until the end of 2027 being well below the historical 16% p.a. growth over the last five years.    By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 4.3% annually.  Even after the forecast slowdown in growth, it seems obvious that Niagen Bioscience is also expected to grow faster than the wider industry.     AdvertisementThe Bottom Line  The most important thing to take away is that analysts cut their earnings per share estimates, expecting a clear decline in business conditions.        While analysts did downgrade their revenue estimates, these forecasts still imply revenues will perform better than the wider market.        After such a stark change in sentiment from analysts, we'd understand if readers now felt a bit wary of Niagen Bioscience.    So things certainly aren't looking great, and you should also know that we've spotted some potential warning signs with Niagen Bioscience, including its declining profit margins.   For more information, you can click here to discover this and the 1 other risk we've identified.  Another way to search for interesting companies that could be  reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682396512","isCrawlerRequest":true}